IGALMI Drug Insight

“IGALMI Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about IGALMI for schizophrenia in the seven major markets. A detailed picture of the IGALMI for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the IGALMI for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the IGALMI market forecast analysis for schizophrenia in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia.

Drug Summary

IGALMI is the first new acute treatment for schizophrenia or bipolar disorder-associated agitation in a decade. It represents a differentiated approach to helping patients manage this difficult and debilitating symptom. Agitation is a common and difficult-to-manage symptom associated with bipolar I or II or schizophrenia. Early identification and prompt intervention to relieve agitation are essential to avoid symptomatic escalation and the emergence of aggression. The FDA approval of IGALMI is based on data from two pivotal randomized, double-blinded, placebo-controlled, parallel-group Phase III trials evaluating IGALMI for the acute treatment of agitation associated with schizophrenia (SERENITY I) or bipolar I or II disorder (SERENITY II).

Dosage and administration

IGALMI is for sublingual or buccal administration. The patient should not chew or swallow IGALMI and should not eat or drink for at least 15 min after sublingual administration or at least 1 h after buccal administration.

Mechanism of action

The mechanism of action of olanzapine is unclear; however, its efficacy in the treatment of schizophrenia or bipolar I disorder could be mediated through a combination of dopamine and serotonin type 2 (5HT2) antagonism.

The mechanism of action of samidorphan could be mediated through opioid receptor antagonism.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the IGALMI description, mechanism of action, dosage and administration, research and development activities in schizophrenia.
• Elaborated details on IGALMI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the IGALMI research and development activities in schizophrenia across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around IGALMI.
• The report contains forecasted sales of for schizophrenia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for schizophrenia.
• The report also features the SWOT analysis with analyst views for IGALMI in schizophrenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IGALMI Analytical Perspective by DelveInsight

• In-depth IGALMI Market Assessment

This report provides a detailed market assessment of IGALMI for schizophrenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• IGALMI Clinical Assessment

The report provides the clinical trials information of IGALMI for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IGALMI dominance.
• Other emerging products for schizophrenia are expected to give tough market competition to IGALMI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IGALMI in schizophrenia.
• Our in-depth analysis of the forecasted sales data of IGALMI from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the IGALMI in schizophrenia.

Key Questions

• What is the product type, route of administration and mechanism of action of IGALMI?
• What is the clinical trial status of the study related to IGALMI in schizophrenia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IGALMI development?
• What are the key designations that have been granted to IGALMI for schizophrenia?
• What is the forecasted market scenario of IGALMI for schizophrenia?
• What are the forecasted sales of IGALMI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to IGALMI for schizophrenia?
• Which are the late-stage emerging therapies under development for the treatment of schizophrenia?